{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T13:50:32Z","timestamp":1776952232749,"version":"3.51.4"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T00:00:00Z","timestamp":1576800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003335","name":"Ministry of Education, Youth and Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003335","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"DOI":"10.3389\/fpubh.2019.00363","type":"journal-article","created":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T14:01:59Z","timestamp":1576850519000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Modeling the Pharmacotherapy Cost and Outcomes of Primary Open-Angle Glaucoma With Dry Eye"],"prefix":"10.3389","volume":"7","author":[{"given":"Konstantin","family":"Tachkov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anton","family":"Vassilev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanislava","family":"Kostova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2019,12,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1136\/bjo.2005.081224","article-title":"The number of people with glaucoma worldwide in 2010 and 2020","volume":"90","author":"Quigley","year":"2006","journal-title":"Br J Ophthalmol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","article-title":"Global prevalence of glaucoma and projections of glaucoma burden through 2040","volume":"121","author":"Tham","year":"2014","journal-title":"Ophthalmology."},{"key":"B3","volume-title":"Terminology and Guidelines for Glaucoma Therapy.","year":"2014"},{"key":"B4","volume-title":"Shields' Textbook of Glaucoma.","author":"Allingham","year":"2015"},{"key":"B5","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","article-title":"TFOS DEWS II, definition and classification report","volume":"15","author":"Craig","year":"2017","journal-title":"Ocular Surf."},{"key":"B6","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jtos.2017.05.004","article-title":"TFOS DEWS II iatrogenic report","volume":"15","author":"Gomes","year":"2017","journal-title":"Ocular Surf."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1007\/s00417-008-0881-9","article-title":"German register for glaucoma patients with dry eye. I. Basic outcome with respect to dry eye","volume":"246","author":"Erb","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"key":"B8","first-page":"10","article-title":"Dry eye disease \u2013 population screening of the syndrome","volume":"3","author":"Shandurkov","year":"2007","journal-title":"Bulgarian Ophthalmol Rev."},{"key":"B9","doi-asserted-by":"publisher","first-page":"931","DOI":"10.18240\/ijo.2017.06.16","article-title":"Ocular surface evaluation in eyes with chronic glaucoma on long term topical antiglaucoma therapy","volume":"10","author":"Saini","year":"2017","journal-title":"Int J Ophthalmol"},{"key":"B10","first-page":"931","article-title":"Ocular surface evaluation in eyes with chronic glaucoma on long term topical antiglaucoma therapy","volume":"10","author":"Saini","year":"2017","journal-title":"Int J Ophthalmol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"707","DOI":"10.2147\/OPTH.S150816","article-title":"Glaucoma therapy: preservative-free for all?","volume":"12","author":"Thygesen","year":"2018","journal-title":"Clin Ophthalmol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.preteyeres.2010.03.001","article-title":"Preservatives in eyedrops: the good, the bad and the ugly","volume":"29","author":"Baudouin","year":"2010","journal-title":"Prog Retin Eye Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1080\/17425255.2016.1209481","article-title":"Ocular surface toxicity from glaucoma topical medications and associated preservatives such as benzalkonium chloride (BAK)","volume":"12","author":"Aguayo Bonniard","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.sjopt.2014.09.003","article-title":"Dry eye and ocular surface disease","volume":"28","author":"Yiu","year":"2014","journal-title":"Saudi J Ophthalmol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1159\/000334791","article-title":"Ocular surface and external filtration surgery: mutual relationships","volume":"50","author":"Baudouin","year":"2012","journal-title":"Dev Ophthalmol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1001\/archopht.1994.01090230060021","article-title":"Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery","volume":"112","author":"Broadway","year":"1994","journal-title":"Arch Ophthalmol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.ajo.2005.04.051","article-title":"Persistence and adherence with topical glaucoma therapy","volume":"140","author":"Nordstrom","year":"2005","journal-title":"Am J Ophthalmol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"696328","DOI":"10.1155\/2013\/696328","article-title":"How ocular surface disease impacts the glaucoma treatment outcome","volume":"2013","author":"Kastelan","year":"2013","journal-title":"Biomed Res Int."},{"key":"B19","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1093\/fampra\/cmu031","article-title":"Factors associated with adherence to glaucoma pharmacotherapy in the primary care setting","volume":"31","author":"Cohen Castel","year":"2014","journal-title":"Fam Pract."},{"key":"B20","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1177\/112067210901900409","article-title":"Dry eye syndrome-related quality of life in glaucoma patients","volume":"19","author":"Rossi","year":"2009","journal-title":"Eur J Ophthalmol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/j.1442-9071.2004.00782.x","article-title":"Corneal epithelial cellular dysfunction from benzalkonium chloride (BAC) in vitro","volume":"32","author":"Cha","year":"2004","journal-title":"Clin Experiment Ophthalmol."},{"key":"B22","first-page":"619","article-title":"Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells","volume":"40","author":"De Saint Jean","year":"1999","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.4066\/biomedicalresearch.29-18-832","article-title":"Objective assessment of ocular surface as an important prognostic factor for dry eye development in patients with glaucoma","volume":"29","author":"Vassilev","year":"2018","journal-title":"Biomedical Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/j.ophtha.2008.12.034","article-title":"Glaucoma and dry eye","volume":"116","author":"Ali","year":"2009","journal-title":"Ophtalmology."},{"key":"B25","unstructured":"DanchevN\n            NikolovaI\n            VassilevaM\n            TerezovaS\n            ZidarovaB\n            ApostolovaD\n          National Council of Prices and Reimbursement of Medicinal Products"},{"key":"B26","doi-asserted-by":"publisher","first-page":"925","DOI":"10.2471\/BLT.15.164418","article-title":"Cost\u2013effectiveness thresholds: pros and cons","volume":"94","author":"Bertram","year":"2016","journal-title":"Bull World Health Organ."},{"key":"B27","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1136\/bjophthalmol-2016-EGSguideline.003","article-title":"4th Edition - Chapter 3: Treatment principles and options","volume":"101","year":"2017","journal-title":"Brit J Ophthalmol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1016\/j.ophtha.2010.03.003","article-title":"Comparison of comorbid conditions between open-angle glaucoma patients and a control cohort: a case-control study","volume":"117","author":"Lin","year":"2010","journal-title":"Ophthalmology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1017\/S0266462399015299","article-title":"Modeling cost of treatment with new topical treatments for glaucoma. Results from France and the United Kingdom","volume":"15","author":"Kobelt","year":"1999","journal-title":"Int J Technol Assess Healthcare."},{"key":"B30","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1007\/BF02850198","article-title":"Switching patients with glaucoma or ocular hypertension from dual therapy to monotherapy: evaluation of brimonidine as a model","volume":"18","author":"Abelson","year":"2001","journal-title":"Adv Ther."},{"key":"B31","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/j.1755-3768.2011.02318.x","article-title":"The long-term outcomes of four alternative treatment strategies for primary open-angle glaucoma Acta Ophthalmol","volume":"90","author":"van Gestel","year":"2012"},{"key":"B32","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/j.1755-3768.2009.01857.x","article-title":"Latanoprost versus timolol as first choice therapy in patients with ocular hypertension. A cost-effectiveness analysis","volume":"90","author":"Peeters","year":"2012","journal-title":"Acta Ophthalmol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/j.ajo.2005.06.030","article-title":"Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications","volume":"141","author":"Noecker","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/sj.eye.6702964","article-title":"Cost-effectiveness of latanoprost and timolol maleate for the treatment of glaucoma in Scandinavia and the United Kingdom, using a decision-analytic health economic model","volume":"23","author":"Stewart","year":"2009","journal-title":"Eye."},{"key":"B35","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2165\/0044011-200929020-00005","article-title":"Cost-effectiveness of travoprost versus a fixed combination of latanoprost\/timolol in patients with ocular hypertension or glaucoma: analysis based on the UK general practitioner research database","volume":"29","author":"De Natale","year":"2009","journal-title":"Clin Drug Investig"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1185\/030079908X280626","article-title":"A cost-effectiveness analysis of fixed-combination therapies in patients with open-angle glaucoma: a European perspective","volume":"24","author":"Hommer","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"B37","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1136\/bjo.2005.076117","article-title":"The rising cost of glaucoma drugs in Ireland 1996-2003","volume":"90","author":"Knox","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/j.1395-3907.2004.00295.x","article-title":"How prostaglandins have changed the medical approach to glaucoma and its costs: an observational study of 2228 patients treated with glaucoma medications","volume":"82","author":"De Natale","year":"2004","journal-title":"Acta Ophthalmol Scand"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1136\/bjo.2005.067355","article-title":"Direct costs of glaucoma and severity of the disease: a multinational long-term study of resource utilisation in Europe","volume":"89","author":"Traverso","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"E3043","DOI":"10.3390\/ijerph16173043","article-title":"Underlying differences in health spending within the World Health Organisation Europe Region\u2014Comparing EU15, EU Post-2004, CIS, EU Candidate, and CARINFONET countries","volume":"16","author":"Jakovljevic","year":"2019","journal-title":"Int J Environ Res Publ Health."},{"key":"B41","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1080\/13696998.2019.1600523","article-title":"Comparative financing analysis and political economy of noncommunicable diseases","volume":"22","author":"Jakovljevic","year":"2019","journal-title":"J Med Econ."},{"key":"B42","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3389\/fpubh.2018.00052","article-title":"Systematic review of health economic evaluation studies developed in Brazil from 1980 to 2013","volume":"6","author":"Decimoni","year":"2018","journal-title":"Front Public Health"},{"key":"B43","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.ophtha.2008.12.056","article-title":"The Cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States","volume":"116","author":"Rein","year":"2009","journal-title":"Ophthalmology."},{"key":"B44","doi-asserted-by":"publisher","first-page":"3394","DOI":"10.1167\/iovs.12-11549","article-title":"Cost-effectiveness of treating normal tension glaucoma","volume":"54","author":"Li","year":"2013","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.3390\/ijms18071398","article-title":"Dry Eye Management: Targeting the Ocular Surface Microenvironment","volume":"18","author":"Zhang","year":"2017","journal-title":"Int J Mol Sci."},{"key":"B46","unstructured":"BaetenR\n            SpasovaS\n            Van HerckeB\n            CosterS\n          Inequalities in Access to Healthcare A Study of National Policies 2018."},{"key":"B47","doi-asserted-by":"publisher","first-page":"892","DOI":"10.3389\/fphar.2017.00892","article-title":"Pharmaceutical regulation in central and eastern European countries: a current review","volume":"8","author":"Kawalec","year":"2017","journal-title":"Front Pharmacol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.2147\/OPTH.S41358","article-title":"Preservative toxicity in glaucoma medication: clinical evaluation of benzalkonium chloride-free 0.5% timolol eye drops","volume":"7","author":"Rosin","year":"2013","journal-title":"Clin Ophthalmol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"131","DOI":"10.17925\/USOR.2014.07.02.131","article-title":"Cost-effectiveness in the treatment of glaucoma","volume":"7","author":"Chan","year":"2014","journal-title":"US Ophthalmic Rev"},{"key":"B50","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1590\/S0004-27492012000100002","article-title":"Cost-effectiveness comparison between non-penetrating deep sclerectomy and maximum-tolerated medical therapy for glaucoma within the Brazilian National Health System (SUS)","volume":"75","author":"Guedes","year":"2012","journal-title":"Arq Bras Oftalmol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S0002-9394(01)01028-5","article-title":"The Advanced Glaucoma Intervention Study (AGIS): 9. Comparison of glaucoma outcomes in black and white patients within treatment groups","volume":"132","author":"AGIS","year":"2001","journal-title":"Am J Ophthalmol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.ophtha.2003.09.025","article-title":"The Advanced Glaucoma Intervention Study (AGIS): 13. Comparison of treatment outcomes within race: 10-year results","volume":"111","author":"Ederer","year":"2004","journal-title":"Ophthalmology."},{"key":"B53","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/BF00133936","article-title":"Argon laser trabeculoplasty in primary open-angle glaucoma\u2013results in black Jamaican population","volume":"12","author":"Moriarty","year":"1988","journal-title":"Int Ophthalmol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1001\/archophthalmol.2010.83","article-title":"Effect of patient's life expectancy on the cost-effectiveness of treatment for ocular hypertension","volume":"128","author":"Kymes","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/OPX.0b013e3181fc30f3","article-title":"Cost-effectiveness of glaucoma interventions in Barbados and Ghana","volume":"88","author":"Wittenborn","year":"2011","journal-title":"Optom Vis Sci"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fpubh.2019.00363\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T14:02:03Z","timestamp":1576850523000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fpubh.2019.00363\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,20]]},"references-count":55,"alternative-id":["10.3389\/fpubh.2019.00363"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2019.00363","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,20]]},"article-number":"363"}}